Dr. Dong Hyun Kim, Seoul National University College of Medicine, South Korea
Dong Hyun Kim, born on April 16, 1993, in South Korea, is a clinical researcher and physician specializing in clinical oncology, hematologic malignancy, and translational medicine. He is currently an external clinical researcher in the Division of Hemato-Oncology at Seoul National University Hospital. Dr. Kim earned his Bachelor of Medicine from Seoul National University College of Medicine in 2019, followed by a Master of Medical Science in Translational Medicine, expected in 2024. He has held positions as an intern and resident doctor in internal medicine at Seoul National University Hospital. Dr. Kim’s research has garnered numerous honors, including the Best Oral Presentation Awards at ICBMT 2022 and ICKSH 2024, as well as the prestigious Presidential Oral Presentation at JSMO 2024.
Professional Profile:
ORCID
SCOPUS
Summary of Suitability for Best Researcher Award: Dong Hyun Kim
Research Excellence: Dong Hyun Kim has demonstrated exceptional contributions to the fields of Clinical Oncology and
Hematologic Malignancy, focusing on translational medicine. His publication record showcases a robust output of 37
articles, with significant works in high-impact journals such as Cells, British Journal of Haematology, and Scientific Reports.
His research spans critical topics, including tumor microenvironments, therapeutic strategies, and the role of artificial
intelligence in oncology
Education:
🎓 Seoul National University College of Medicine, Seoul, Korea
- Bachelor of Medicine (2015 ~ 2019)
- Master of Medical Science, Department of Translational Medicine (2022 ~ 2024)
Professional Experience:
🏥 Seoul National University Hospital
- Intern (2019 ~ 2020)
- Resident Doctor, Department of Internal Medicine (2020 ~ 2023)
- External Clinical Researcher, Division of Hemato-Oncology (2023 ~ Present)
Honors & Awards 🏅:
- Best Oral Presentation Award, ICBMT 2022
- Presidential Oral Presentation, JSMO 2024
- Best Oral Presentation Award, ICKSH 2024
Publication top Notes:
Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation
Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome
Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies in Korea
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma